Lv41
645 积分 2021-03-08 加入
Taking the individual bias out of examining comparability of biosimilars: A case study on monoclonal antibody therapeutics
6个月前
已完结
From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies
6个月前
已完结
The antibody–drug conjugate landscape
7个月前
已完结
Risk-Based Approach to Setting Sterile Filtration Microbial Bioburden Limits – Focus on Biotech-derived Products
1年前
已完结
Non-specificity as the sticky problem in therapeutic antibody development
1年前
已完结
In-use stability studies: guidelines and challenges
1年前
已完结
Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product
2年前
已完结
Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product
2年前
已完结
A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads
2年前
已完结
皖公网安备34019202002308
